Bradford Crutchfield - 12 Nov 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Issuer symbol
TXG
Transactions as of
12 Nov 2021
Net transactions value
-$2,783,837
Form type
4
Filing time
16 Nov 2021, 17:47:44 UTC
Previous filing
14 Oct 2021
Next filing
24 Nov 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $19,720 +17,000 +39% $1.16 60,336 12 Nov 2021 Direct F1
transaction TXG Class A Common Stock Sale $167,994 -1,030 -1.7% $163.10 59,306 12 Nov 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale $676,733 -4,122 -7% $164.18 55,184 12 Nov 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale $1,132,963 -6,872 -12% $164.87 48,312 12 Nov 2021 Direct F1, F4
transaction TXG Class A Common Stock Sale $792,306 -4,776 -9.9% $165.89 43,536 12 Nov 2021 Direct F1, F5
transaction TXG Class A Common Stock Sale $16,727 -100 -0.23% $167.27 43,436 12 Nov 2021 Direct F1
transaction TXG Class A Common Stock Sale $16,834 -100 -0.23% $168.34 43,336 12 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -17,000 -3.7% $0.000000 443,000 12 Nov 2021 Class A Common Stock 17,000 $1.16 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $162.49 to $163.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $163.50 to $164.495. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $164.50 to $165.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $165.51 to $166.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 This option, originally for 800,000 shares, of which 357,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.